SCHEMBL3603893

SCHEMBL3603893

CC(C)(C)OC(=O)C1CNCC2C(=O)N(c3cccc(Cc4ccccc4)c3)CN12

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.35
PLA2G10 O15496 1/20 0.35
PLA2G5 P39877 1/20 0.35
NR1H2 P55055 4/20 0.34
NR1H3 Q13133 4/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
HRH1 P35367 1/20 0.32
SLC5A1 P13866 1/20 0.32
SLC6A2 P23975 1/20 0.32
CACNA2D1 P54289 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HTR2C P28335 1/20 0.32
MAOA P21397 1/20 0.32
ADAM17 P78536 1/20 0.32
STS P08842 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610736 0.90 ALDH1A1 (0.35) USP30PLA2G10PLA2G5NR1H2NR1H3
SCHEMBL3607457 0.89 USP30 (0.44) USP30NR1H2NR1H3DDB1CRBN
SCHEMBL3604816 0.88 GPR119 (0.36) USP30PLA2G10PLA2G5NR1H2NR1H3
SCHEMBL3595736 0.87 FKBP1A (0.36) USP30NR1H2NR1H3DDB1CRBN
SCHEMBL3605596 0.86 ALDH1A1 (0.37) DDB1CRBNKMT2AL3MBTL1HTR2C
SCHEMBL3601055 0.85 GPR119 (0.41) NR1H2NR1H3KMT2AMAOA
SCHEMBL3597127 0.85 DDB1 (0.34) USP30NR1H2NR1H3DDB1CRBN
SCHEMBL3606120 0.85 POLB (0.37) DDB1CRBNHTR2C
SCHEMBL3606731 0.85 OPRM1 (0.38) USP30NR1H2NR1H3DDB1CRBN
SCHEMBL3609983 0.84 ALDH1A1 (0.36) USP30NR1H2NR1H3DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A USP30 4815/4885PLA2G10 3043/4885PLA2G5 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.